Benjamin Daniel K, Stoll Barbara J, Fanaroff Avory A, McDonald Scott A, Oh William, Higgins Rosemary D, Duara Shahnaz, Poole Kenneth, Laptook Abbot, Goldberg Ronald
Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
Pediatrics. 2006 Jan;117(1):84-92. doi: 10.1542/peds.2004-2292.
Neonatal candidiasis is associated with substantial morbidity and mortality rates. Neurodevelopmental follow-up data for a large multicenter cohort have not been reported.
Data were collected prospectively for neonates born at <1000 g at National Institute of Child Health and Human Development-sponsored Neonatal Research Network sites between September 1, 1998, and December 31, 2001. Uniform follow-up evaluations, including assessments of mental and motor development with the Bayley Scales of Infant Development II, were completed for all survivors at corrected ages of 18 to 22 months. We evaluated risk factors for the development of neonatal candidiasis, responses to antifungal therapy, and the association between candidiasis and subsequent morbidity and death.
The cohort consisted of 4579 infants; 320 of 4579 (7%) developed candidiasis; 307 of 320 had Candida isolated from blood, 27 of 320 had Candida isolated from cerebrospinal fluid, and 13 (48%) of 27 of those with meningitis had negative blood cultures. In multivariate analysis of risk factors on day of life 3, birth weight, cephalosporins, gender, and lack of enteral feeding were associated with development of candidiasis. After diagnosis, most neonates had multiple positive cultures despite antifungal therapy, and 10% of neonates had candidemia for > or =14 days. Death or neurodevelopmental impairment (NDI) was observed for 73% of extremely low birth weight infants who developed candidiasis. Death and NDI rates were greater for infants who had delayed removal or replacement of central catheters (>1 day after initiation of antifungal therapy), compared with infants whose catheters were removed or replaced promptly.
Blood cultures were negative for approximately one half of the infants with Candida meningitis. Persistent candidiasis was common. Delayed catheter removal was associated with increased death and NDI rates.
新生儿念珠菌病与较高的发病率和死亡率相关。尚未有大型多中心队列的神经发育随访数据报道。
前瞻性收集了1998年9月1日至2001年12月31日期间在美国国立儿童健康与人类发展研究所资助的新生儿研究网络站点出生体重<1000g的新生儿的数据。对所有存活者在矫正年龄18至22个月时完成了统一的随访评估,包括使用贝利婴幼儿发展量表第二版进行智力和运动发育评估。我们评估了新生儿念珠菌病发生的危险因素、抗真菌治疗的反应以及念珠菌病与随后的发病率和死亡率之间的关联。
该队列由4579名婴儿组成;4579名中有320名(7%)发生了念珠菌病;320名中有307名血培养分离出念珠菌,320名中有27名脑脊液分离出念珠菌,27名患脑膜炎的患儿中有13名(48%)血培养阴性。在出生后第3天危险因素的多变量分析中,出生体重、头孢菌素、性别和未进行肠内喂养与念珠菌病的发生相关。诊断后,大多数新生儿尽管接受了抗真菌治疗仍有多次阳性培养结果,10%的新生儿念珠菌血症持续≥ 14天。发生念珠菌病 的极低出生体重儿中有73%出现死亡或神经发育障碍(NDI)。与导管及时拔除或更换的婴儿相比,导管拔除或更换延迟(抗真菌治疗开始>1天后)的婴儿死亡和NDI发生率更高。
约一半念珠菌性脑膜炎婴儿的血培养结果为阴性。持续性念珠菌病很常见。导管拔除延迟与死亡和NDI发生率增加相关。